Nice recommends Lucentis (Novartis) for Macular Oedema following RVO

NICE has issued final draft guidance recommending Lucentis (ranibizumab), from Novartis, as a treatment for sight problems caused by Macular Oedema following central retinal vein occlusion (CRVO), provided Novartis makes the drug available under an agreed patient access scheme (PAS). It also recommends it as a treatment option following branch retinal vein occlusion (BRVO) when standard treatment with laser photocoagulation has not worked, or when it is not suitable because of the extent of macular haemorrhage.